Bionomics Ltd ADR (BNOX)

$0.25 +0.01 (4.20%)
Market Cap 4.47M
Revenue (ttm) 0.00
Net Income (ttm) -15.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 7,434,400
Avg Vol 12,314,951
Day's Range N/A - N/A
Shares Out 17.65M
Stochastic %K 20%
Beta 0.26
Analysts Strong Sell
Price Target $6.00
frontiere
frontiere Jan. 28 at 9:43 PM
$NEUP Neuphoria ex $BNOX Bionomics 👇 and to be clear, any deal takes time to draft negotiate structure review etc, I’ve worked on them and it can take weeks to months if thorough enough and esp if shopped around. So no clue if we are talking here days or months till some finale. But think highly likely some deal will come. Just that the timing and price levels will make a big difference for us, longs
0 · Reply
frontiere
frontiere Jan. 28 at 6:30 PM
$BNOX $NEUP Bionomics Neuphoria - on 9 Jan CEO moves to consulting setup with change of control earnouts if within 12 months - and afterwards still crickets. No Lynx1 news…
1 · Reply
frontiere
frontiere Jan. 2 at 8:35 PM
$NEUP Neuphoria ex $BNOX Bionomics ref=$3.89 — Long again — nobody noticed the new proposal 2025-12-26 from Lynx1 Weston Nichols to buy some IP assets from NEUP for cash or similar stock consideration? 👍 As the old offer of the $4.75 cash takeover got spurned by NEUP. Bullish! 13D https://www.sec.gov/Archives/edgar/data/1191070/000090514825004208/xslSCHEDULE_13D_X01/primary_doc.xml Prior see my long history of posts on name.
0 · Reply
frontiere
frontiere Dec. 1 at 3:00 PM
$NEUP Neuphoria ex $BNOX Bionomics ref=$4.50 — NO PSTN since before the SAD readout 👇 but watching the drama w Lynx1 vs NEUP activist campaign. Very interesting table in the PR. https://lifesciencereport.com/news/nasdaq/neup/neuphoria-provides-facts-exposes-false-narratives-in-response-to-lynx1-fictions
0 · Reply
topstockalerts
topstockalerts Oct. 24 at 1:35 PM
$BNOX it wants to squeeze higher.. âś…
0 · Reply
5Aminthebigapple
5Aminthebigapple Oct. 21 at 8:44 PM
$BNOX https://youtube.com/shorts/wolSVRn1WlU?si=0QdjAabCAQXZEsvF watch an sub
0 · Reply
JcCapital
JcCapital Oct. 9 at 3:30 AM
$BNOX will it go to $25 ?
0 · Reply
XQuise
XQuise Oct. 3 at 7:43 PM
$BNOX 🤑👋
0 · Reply
vision_in_motion94
vision_in_motion94 Sep. 25 at 5:12 PM
$BNOX NXXT shorts playing with fire if contracts land, thin float plus real numbers equals painful squeeze potential 🔥
0 · Reply
caidenhutchinson
caidenhutchinson Sep. 25 at 4:56 PM
$BNOX NXXT underfollowed microcap with operating leverage, once the street models it properly this should command far better multiples
0 · Reply
Latest News on BNOX
Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation

Dec 16, 2024, 4:05 PM EST - 1 year ago

Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation

Results of Scheme Meeting

Dec 12, 2024, 4:05 PM EST - 1 year ago

Results of Scheme Meeting

Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting

Dec 3, 2024, 4:05 PM EST - 1 year ago

Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting

Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States

Dec 2, 2024, 5:01 PM EST - 1 year ago

Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States

Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement

Nov 8, 2024, 4:15 PM EST - 1 year ago

Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement

Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program

Nov 4, 2024, 4:15 PM EST - 1 year ago

Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program

Bionomics to Present at the ThinkEquity Conference

Oct 23, 2024, 6:00 AM EDT - 1 year ago

Bionomics to Present at the ThinkEquity Conference

Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Bionomics Limited announces intention to re-domicile to the United States

Oct 1, 2024, 6:30 AM EDT - 1 year ago

Bionomics Limited announces intention to re-domicile to the United States

Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 6:30 AM EDT - 1 year ago

Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder

Jul 31, 2024, 6:30 AM EDT - 1 year ago

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder

Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024

Jul 29, 2024, 4:30 PM EDT - 1 year ago

Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024

Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder

Jul 18, 2024, 6:30 AM EDT - 1 year ago

Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder

Bionomics Limited Announces Private Placement of up to $70.0 Million

May 31, 2024, 8:00 AM EDT - 1 year ago

Bionomics Limited Announces Private Placement of up to $70.0 Million

Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

May 20, 2024, 6:30 AM EDT - 1 year ago

Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

Mar 21, 2024, 6:00 AM EDT - 2 years ago

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

Bionomics to Present at the 2024 BIO CEO & Investor Conference

Feb 22, 2024, 4:30 PM EST - 2 years ago

Bionomics to Present at the 2024 BIO CEO & Investor Conference

Bionomics Provides a Review of 2023 and of 2024 Plans

Jan 22, 2024, 6:00 AM EST - 2 years ago

Bionomics Provides a Review of 2023 and of 2024 Plans

Bionomics to Present at Biotech Showcase™ 2024

Jan 5, 2024, 6:00 AM EST - 2 years ago

Bionomics to Present at Biotech Showcase™ 2024

Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting

Dec 6, 2023, 8:00 AM EST - 2 years ago

Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder

Bionomics announces positive results in trial of treatment for PTSD

Sep 28, 2023, 6:13 AM EDT - 2 years ago

Bionomics announces positive results in trial of treatment for PTSD

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

Sep 28, 2023, 6:00 AM EDT - 2 years ago

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

Sep 14, 2023, 6:00 AM EDT - 2 years ago

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210

Aug 23, 2023, 6:00 AM EDT - 2 years ago

Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210

Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)

Jul 25, 2023, 6:00 AM EDT - 2 years ago

Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)

Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

Jul 3, 2023, 6:00 AM EDT - 2 years ago

Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

Bionomics to Present at Upcoming June Investor Conferences

Jun 15, 2023, 8:00 AM EDT - 2 years ago

Bionomics to Present at Upcoming June Investor Conferences

Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

May 30, 2023, 6:00 AM EDT - 2 years ago

Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

Apr 27, 2023, 6:00 AM EDT - 3 years ago

Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)

Mar 8, 2023, 7:00 PM EST - 3 years ago

Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)

Bionomics' Half-Year Report

Feb 23, 2023, 6:00 AM EST - 3 years ago

Bionomics' Half-Year Report

Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder

Dec 18, 2022, 7:34 PM EST - 3 years ago

Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder

Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer

Dec 15, 2022, 6:35 PM EST - 3 years ago

Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer

Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

Dec 2, 2022, 6:00 AM EST - 3 years ago

Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States

Nov 21, 2022, 6:13 PM EST - 3 years ago

Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States

Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States

Nov 16, 2022, 6:36 PM EST - 3 years ago

Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States

Bionomics Limited to Participate in Upcoming November Investor Conferences

Nov 2, 2022, 6:00 AM EDT - 3 years ago

Bionomics Limited to Participate in Upcoming November Investor Conferences

Quarterly Activities Report for September 2022

Oct 25, 2022, 6:00 AM EDT - 3 years ago

Quarterly Activities Report for September 2022

Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million

Oct 18, 2022, 6:00 AM EDT - 3 years ago

Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million

Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference

Oct 4, 2022, 6:00 AM EDT - 3 years ago

Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference

Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder

Sep 21, 2022, 6:00 AM EDT - 3 years ago

Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder

Bionomics to Participate in Upcoming September Investor Conferences

Aug 31, 2022, 6:00 AM EDT - 3 years ago

Bionomics to Participate in Upcoming September Investor Conferences

Bionomics reports Full Year Financial Results

Aug 25, 2022, 6:00 AM EDT - 3 years ago

Bionomics reports Full Year Financial Results

Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M

Aug 8, 2022, 6:00 AM EDT - 3 years ago

Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M

Quarterly Activities Report for June 2022

Jul 29, 2022, 6:00 AM EDT - 3 years ago

Quarterly Activities Report for June 2022

Bionomics to Participate in William Blair's Biotech Focus Conference 2022

Jul 8, 2022, 6:00 AM EDT - 3 years ago

Bionomics to Participate in William Blair's Biotech Focus Conference 2022

Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference

Jun 27, 2022, 6:00 AM EDT - 3 years ago

Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference

Bionomics Investor Webinar

Jun 13, 2022, 4:30 PM EDT - 3 years ago

Bionomics Investor Webinar

Bionomics Limited to Participate in Upcoming Investor Conferences

May 16, 2022, 6:00 AM EDT - 4 years ago

Bionomics Limited to Participate in Upcoming Investor Conferences

frontiere
frontiere Jan. 28 at 9:43 PM
$NEUP Neuphoria ex $BNOX Bionomics 👇 and to be clear, any deal takes time to draft negotiate structure review etc, I’ve worked on them and it can take weeks to months if thorough enough and esp if shopped around. So no clue if we are talking here days or months till some finale. But think highly likely some deal will come. Just that the timing and price levels will make a big difference for us, longs
0 · Reply
frontiere
frontiere Jan. 28 at 6:30 PM
$BNOX $NEUP Bionomics Neuphoria - on 9 Jan CEO moves to consulting setup with change of control earnouts if within 12 months - and afterwards still crickets. No Lynx1 news…
1 · Reply
frontiere
frontiere Jan. 2 at 8:35 PM
$NEUP Neuphoria ex $BNOX Bionomics ref=$3.89 — Long again — nobody noticed the new proposal 2025-12-26 from Lynx1 Weston Nichols to buy some IP assets from NEUP for cash or similar stock consideration? 👍 As the old offer of the $4.75 cash takeover got spurned by NEUP. Bullish! 13D https://www.sec.gov/Archives/edgar/data/1191070/000090514825004208/xslSCHEDULE_13D_X01/primary_doc.xml Prior see my long history of posts on name.
0 · Reply
frontiere
frontiere Dec. 1 at 3:00 PM
$NEUP Neuphoria ex $BNOX Bionomics ref=$4.50 — NO PSTN since before the SAD readout 👇 but watching the drama w Lynx1 vs NEUP activist campaign. Very interesting table in the PR. https://lifesciencereport.com/news/nasdaq/neup/neuphoria-provides-facts-exposes-false-narratives-in-response-to-lynx1-fictions
0 · Reply
topstockalerts
topstockalerts Oct. 24 at 1:35 PM
$BNOX it wants to squeeze higher.. âś…
0 · Reply
5Aminthebigapple
5Aminthebigapple Oct. 21 at 8:44 PM
$BNOX https://youtube.com/shorts/wolSVRn1WlU?si=0QdjAabCAQXZEsvF watch an sub
0 · Reply
JcCapital
JcCapital Oct. 9 at 3:30 AM
$BNOX will it go to $25 ?
0 · Reply
XQuise
XQuise Oct. 3 at 7:43 PM
$BNOX 🤑👋
0 · Reply
vision_in_motion94
vision_in_motion94 Sep. 25 at 5:12 PM
$BNOX NXXT shorts playing with fire if contracts land, thin float plus real numbers equals painful squeeze potential 🔥
0 · Reply
caidenhutchinson
caidenhutchinson Sep. 25 at 4:56 PM
$BNOX NXXT underfollowed microcap with operating leverage, once the street models it properly this should command far better multiples
0 · Reply
TraderCelest
TraderCelest May. 1 at 2:38 PM
$BNOX. LGMK volume over 700 million 2 cents and below could be quick money with push....
0 · Reply
frontiere
frontiere Apr. 28 at 3:40 PM
ex $BNOX Bionomics now $NEUP Neuphoria ref=$5.19 — Long — another podcast insight, Citrini Research (James Van Geelen) @Citrini highlighted his Mental Health x SMID micro-themes as bullish — reminder NEUP targets PTSD, SAD and potential other dz in that space, de-risked / validated by their $MRK Merck collab for which they received $15M milestone earlier this yr and are still BELOW CASH (neg EV) Full https://podcasts.apple.com/us/podcast/ep-305-james-van-geelen-on-haves-vs-have-nots-theme/id1502904619
1 · Reply
frontiere
frontiere Mar. 5 at 2:13 PM
$NEUP Neuphoria ex $BNOX Bionomics - somehow StockTwits does not link this post to the tickers I tagged re $CMRX Chimerix deal 👇
1 · Reply
SqueezeMagnet33
SqueezeMagnet33 Jan. 26 at 10:35 PM
$FMST On Squeeze watch . $SLNH Hot $BNOX Hot
0 · Reply
bandido20
bandido20 Jan. 26 at 4:49 PM
$FMST 10 times more watchers just within 36 hours. Beast in the making. CEO recently reaching out on X https://x.com/fmstcleanenergy/status/1883191573359517808?s=46 and spreading awareness of ongoing projects and potential catalyst âś… 6.07 Mil float âś… NO dilution âś… Plenty of cash âś… Offering completed âś… 35% Insider ownership âś… Analyst price target $5.21 âś… Low borrow & high fees âś… Oversold with a 1:6 risk/reward near-term Watching $DDD & $BNOX for continuation $NEUP I like
0 · Reply
frankyboyz
frankyboyz Jan. 24 at 9:15 PM
trade idea, took some $ACCS into monday, will ticker and name change from $ACCS into $ACCS - Access Newswire. Resistances I see are 10/10.50 then can potentially off momo and vol open up nicely. But on those, you do you. Sexy float 2.16m. Last ticker change we had was $BNOX into $$NEUP lol, todays nuts runner. Let’s close the week strong and start the next stronger!!! @everyone
1 · Reply